Immunotherapy最新文献_第3页

Therapeutic lymph node dissection with neoadjuvant immunotherapy for macroscopic melanoma - too much skin in the game? 治疗性淋巴结清扫与新辅助免疫治疗宏观黑色素瘤-太多的皮肤在游戏中？

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-07-01 DOI: 10.1080/1750743X.2025.2527574

Sze Wah Samuel Chan, Michael Au, Adi Kartolo

引用次数: 0

Chemotherapy-free treatment of B-lymphoid/myeloid mixed phenotype acute leukemia: two case reports and literature review. 无化疗治疗b淋巴/髓混合表型急性白血病2例报告并文献复习。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-07-13 DOI: 10.1080/1750743X.2025.2527018

Yi-Fan Wang, Jing-Ying Dai, Ming-Yong Li, Tao Jiang

{"title":"Chemotherapy-free treatment of B-lymphoid/myeloid mixed phenotype acute leukemia: two case reports and literature review.","authors":"Yi-Fan Wang, Jing-Ying Dai, Ming-Yong Li, Tao Jiang","doi":"10.1080/1750743X.2025.2527018","DOIUrl":"10.1080/1750743X.2025.2527018","url":null,"abstract":"B-lymphoid/myeloid mixed phenotype acute leukemia (MPAL) is a rare subtype of acute leukemia that most likely originates from hematopoietic pluripotent stem cells. It is a heterogeneous group of leukemia characterized by the expression of more than 1 specific marker from each hematopoietic lineage (lymphoid and myeloid-specific antigens). The MLL-AF4 fusion gene is a common genetic abnormality in MPAL. Due to the lack of thorough understanding and the rare occurrence of B-lymphoid/myeloid MPAL, it presents substantial challenges in determining the standard treatment protocol. The absence of a widely accepted optimal treatment for MPAL has indicated the need for a more effective and less toxic approach. This case report presents two cases of B-lymphoid/myeloid MPAL with MLL-AF4 genetic abnormality successfully treated with a chemo-free regimen composed of venetoclax, hypomethylating agents, and blinatumomab and achieved complete remission (CR). Considering the results of this case report, the combination of a chemotherapy-free regimen could be considered a safe and effective treatment approach for patients with B-lymphoid/myeloid MPAL.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"639-647"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biology-driven therapies of CAR T immune effector cell-associated neurotoxicity syndrome. CAR - T免疫效应细胞相关神经毒性综合征的生物学驱动疗法。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-01 Epub Date: 2025-05-29 DOI: 10.1080/1750743X.2025.2510893

Sophie Giesler, Francesca Biavasco, Tobias Wertheimer, Robert Zeiser, Janaki Manoja Vinnakota

引用次数: 0

Dietary impacts on prostate cancer immunotherapy. 饮食对前列腺癌免疫治疗的影响。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-01 Epub Date: 2025-05-29 DOI: 10.1080/1750743X.2025.2511472

Loan D Duong, Xin Lu

{"title":"Dietary impacts on prostate cancer immunotherapy.","authors":"Loan D Duong, Xin Lu","doi":"10.1080/1750743X.2025.2511472","DOIUrl":"10.1080/1750743X.2025.2511472","url":null,"abstract":"Prostate cancer is a leading cause of cancer-related mortality in men. While early-stage disease is readily treated, advanced-stage prostate cancer has a poor survival rate and limited effective therapies. Immunotherapy has achieved significant success in other malignancies, but prostate cancer is characterized by an immunosuppressive, \"cold\" tumor microenvironment that blunts immunotherapy efficacy. Emerging evidence suggests that dietary interventions - such as ketogenic diets, methionine restriction, and bioactive compounds like white button mushroom extract - can modulate the tumor microenvironment and enhance immunotherapy responses in preclinical and early clinical studies. Additionally, specific diet-derived factors (such as the ketone body β-hydroxybutyrate) have demonstrated anti-tumor immune effects on their own, representing new avenues for combination therapy. While prior reviews have addressed diet or immunotherapy in prostate cancer independently, this review integrates these domains with the aim of offering a streamlined perspective. This brief review synthesizes recent findings on dietary modulation of prostate cancer immunity, with a focus on mechanistic insights that may be leveraged to augment immunotherapy, to suggest potential combination strategies and inform future translational efforts.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"525-536"},"PeriodicalIF":2.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating remibrutinib in the treatment of chronic spontaneous urticaria. 评价瑞米鲁替尼治疗慢性自发性荨麻疹的疗效。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-01 Epub Date: 2025-06-02 DOI: 10.1080/1750743X.2025.2510892

Agnieszka Bożek, Adam Reich

{"title":"Evaluating remibrutinib in the treatment of chronic spontaneous urticaria.","authors":"Agnieszka Bożek, Adam Reich","doi":"10.1080/1750743X.2025.2510892","DOIUrl":"10.1080/1750743X.2025.2510892","url":null,"abstract":"Chronic spontaneous urticaria (CSU) is a complex inflammatory skin condition that significantly impacts patients' quality of life. Conventional treatments, such as antihistamines, often fail to provide adequate symptom control. The next step involves administering omalizumab, a monoclonal antibody targeting IgE, however, a subset of patients may not respond to this treatment underscoring the necessity for alternative treatment options. Remibrutinib, an oral, selective inhibitor of Bruton's tyrosine kinase (BTK), has emerged as a promising therapy in CSU. BTK is vital for the activation of mast cells and basophils. The inhibitory action of remibrutinib on BTK may help alleviate CSU symptoms by addressing mast cell-mediated inflammation. Clinical trials, including Phase II and III studies, have shown promising efficacy and a favorable safety profile for remibrutinib in treating CSU. Patients experienced rapid symptom relief, with notable improvements in the Urticaria Activity Score (UAS7) concerning both itch intensity and the severity of hives. The safety profile was also commendable, with no significant treatment-related adverse events requiring therapy cessation or posing immediate health risks to patients. These results indicate that remibrutinib may become a preferred oral treatment for patients with moderate to severe CSU who do not adequately respond to standard therapies.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"479-484"},"PeriodicalIF":2.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The complexities of PD-L1 expression as an indicator of immunotherapy outcomes. PD-L1表达的复杂性是免疫治疗结果的一个指标。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-01 Epub Date: 2025-05-05 DOI: 10.1080/1750743X.2025.2500908

Robert A Needleman, Alesha A Thai

引用次数: 0

A case report of mesalazine alleviating diarrhea in a patient with nasopharyngeal cancer after tislelizumab treatment. 美沙拉嗪缓解鼻咽癌患者在替利单抗治疗后腹泻的病例报告。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-01 Epub Date: 2025-05-11 DOI: 10.1080/1750743X.2025.2504323

Xiaomei Zhou, Yu Shu, Xi Chen, Bo Luo

{"title":"A case report of mesalazine alleviating diarrhea in a patient with nasopharyngeal cancer after tislelizumab treatment.","authors":"Xiaomei Zhou, Yu Shu, Xi Chen, Bo Luo","doi":"10.1080/1750743X.2025.2504323","DOIUrl":"10.1080/1750743X.2025.2504323","url":null,"abstract":"Immunotherapy has become a significant research focus for cancer treatment in recent years because it can generate enduring immunological responses and has promising therapeutic potential. Nevertheless, excessive stimulation of the immune system may adversely affect healthy organs, which can lead to immune-related toxicities, including gastrointestinal, pulmonary, hepatic, and dermatological toxicities. Among them, gastrointestinal toxicity induced by the immune response is the most common. Immune-associated enteritis has an incidence rate of 8%-27% and is one of the most prevalent forms of gastrointestinal toxicity. Tislelizumab is an approved first-line treatment for individuals with recurrent or metastatic nasopharyngeal cancer functioning as an inhibitor of PD-1. Here, we report a patient with nasopharyngeal carcinoma who developed bloody stools and diarrhea after two cycles of tislelizumab. Abdominal CT revealed intestinal wall thickening with inflammatory exudation. Congestion, edema, and mucosal punctate ulcers were discovered during the colonoscopy. Histopathology confirmed active mucosal inflammation. The initial treatment with loperamide, bifidobacterium tetrad, and norfloxacin failed, but the symptoms improved significantly after switching to metronidazole, mesalazine, and methylprednisolone. This article reviewed a case of immunological enteritis triggered by tislelizumab, demonstrating that mesalazine can markedly alleviate the symptoms of immune-associated enteritis, aiming to enhance future clinical efforts regarding tislelizumab-induced immunological enteritis.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"485-490"},"PeriodicalIF":2.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New onset of hypertension associated with immune checkpoint inhibitor therapy in cancer patients. 癌症患者新发高血压与免疫检查点抑制剂治疗相关

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-01 Epub Date: 2025-05-16 DOI: 10.1080/1750743X.2025.2504868

HangYu Watson, Nolan Holley, Tabot Ntoung Nkongho, Brijesh Patel

{"title":"New onset of hypertension associated with immune checkpoint inhibitor therapy in cancer patients.","authors":"HangYu Watson, Nolan Holley, Tabot Ntoung Nkongho, Brijesh Patel","doi":"10.1080/1750743X.2025.2504868","DOIUrl":"10.1080/1750743X.2025.2504868","url":null,"abstract":"Aim: To evaluate whether immune checkpoint inhibitor (ICI) therapy is associated with a higher incidence of hypertension (HTN) among cancer patients compared to those not treated with ICIs.Materials & methods: This retrospective cohort study utilized data from the TriNetX Research Network, a global database of de-identified electronic health records. Adult patients (≥18 years) with lung, breast, colon, kidney, or skin cancer were categorized based on ICI treatment. Patients with preexisting hypertension were excluded. Propensity score matching (1:1) based on demographics and comorbidities yielded two balanced cohorts of 24,956 patients each. The primary outcome was the incidence of hypertension within one year of cancer diagnosis.Results: The incidence of hypertension was significantly higher in the ICI group (13.2%) compared to the non-ICI group (9.7%). The risk ratio was 1.356 (95% CI: 1.271-1.446), and the odds ratio was 1.410 (95% CI: 1.311-1.516), both with p < 0.001. Kaplan-Meier analysis showed lower hypertension-free survival in the ICI group (log-rank p < 0.001; HR = 1.071).Conclusions: ICI therapy is significantly associated with an increased risk of developing hypertension. These findings support the need for routine cardiovascular monitoring in patients receiving ICI treatment.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"491-499"},"PeriodicalIF":2.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emapalumab treatment in rheumatologic disease-associated hemophagocytic lymphohistiocytosis: a plain language summary. Emapalumab治疗风湿病相关的噬血细胞淋巴组织细胞病：一个简单的语言总结。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-01 Epub Date: 2025-06-17 DOI: 10.1080/1750743X.2025.2509478

Shanmuganathan Chandrakasan, Carl E Allen, Deepika Bhatla, John Carter, May Chien, Robert Cooper, Lauren Draper, Olive S Eckstein, Rabi Hanna, J Allyson Hays, Michelle L Hermiston, Ashley P Hinson, Patricia M Hobday, Michael S Isakoff, Michael B Jordan, Jennifer W Leiding, Renee Modica, Taizo A Nakano, Abiola Oladapo, Sachit A Patel, Priti Pednekar, Mona Riskalla, Susmita N Sarangi, Prakash Satwani, Anand Tandra, Kelly J Walkovich, John D Yee, Adi Zoref-Lorenz, Edward M Behrens

引用次数: 0

Evaluation of antigen agnostic anti-tumor activity and immune memory induced by CBX-15 (alphalex^TM-MMAE) in the rat. CBX-15 （alphalexTM-MMAE）对大鼠抗肿瘤活性及免疫记忆的影响。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-01 Epub Date: 2025-06-03 DOI: 10.1080/1750743X.2025.2510189

Timothy Paradis, Qing Zhang, Laurie Tylaska, Connor Hagen, Theresa Pasqualini, Vishwas Paralkar, Sophia Gayle

{"title":"Evaluation of antigen agnostic anti-tumor activity and immune memory induced by CBX-15 (alphalexTM-MMAE) in the rat.","authors":"Timothy Paradis, Qing Zhang, Laurie Tylaska, Connor Hagen, Theresa Pasqualini, Vishwas Paralkar, Sophia Gayle","doi":"10.1080/1750743X.2025.2510189","DOIUrl":"10.1080/1750743X.2025.2510189","url":null,"abstract":"Aims: To determine whether using a pH-sensitive peptide (CBX-15) for antigen-independent targeting of MMAE to tumors induced anti-tumor efficacy via direct and immunological mechanisms in the rat tumor model.Methods: CBX-15 was assessed for its ability to kill tumor cells and induce immunogenic cell death (ICD) in female Fischer rats bearing syngeneic 13762 mammary adenocarcinoma tumors via in vivo and ex vivo functional assays.Results: CBX-15 demonstrated efficacy, safety and anti-tumor immunologic memory, demonstrated by the ability of both CBX-15-cured and vaccinated rats to reject further tumor challenge. Responding rats exhibited the induction of ICD-induced immunomodulatory activity, including recognition of tumor cells ex vivo, recruitment of TILs and increases in memory CD4+ T lymphocytes in the bone marrow.Conclusion: CBX-15 eradicates tumors by a combination of both direct cytotoxic action of MMAE as well as through the induction of ICD, the latter of which results in long term anti-tumor immunological memory. To our knowledge, this is the first work demonstrating both anti-tumor efficacy and induction of long-term anti-tumor immune memory by a tumor-selective drug in the rat, the species used for preclinical toxicological evaluation. This study provides a strong justification for exploring combination therapies with CBX-15 and other immunomodulators.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"501-512"},"PeriodicalIF":2.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0